Want to see CDIX full AI Analyst Report?
Top Page
Cardiff Lexington
(OTC:CDIX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.01
▼(-93.50% Downside)
Action:Reiterated
Date:10/31/26
The score is held down primarily by weak financial performance (losses, high leverage, and persistent negative operating/free cash flow) and a strongly bearish technical setup (price well below key moving averages with negative MACD). Valuation is hard to assess due to a negative P/E, while the proposed acquisition provides some upside potential but adds material execution and funding risk.
Positive Factors
Strategic Expansion
The proposed acquisition could materially broaden Cardiff Lexington’s musculoskeletal and ancillary healthcare footprint, while increasing integration with Nova Ortho and Spine. If completed successfully, the larger platform may provide a stronger base for durable operating scale and service expansion.
Negative Factors
Profitability Deterioration
The recent earnings profile is weak and unstable, with declining TTM revenue and losses at operating and net income levels. The swing from profitability in 2023 to sizable losses in 2024 through TTM reduces confidence in near-term earnings durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Expansion
The proposed acquisition could materially broaden Cardiff Lexington’s musculoskeletal and ancillary healthcare footprint, while increasing integration with Nova Ortho and Spine. If completed successfully, the larger platform may provide a stronger base for durable operating scale and service expansion.
Read all positive factors
Cardiff Lexington (CDIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$203.29K
Dividend YieldN/A
Average Volume (3M)82.37K
Price to Earnings (P/E)―
Beta (1Y)0.16
Revenue Growth0.31%
EPS Growth6.99%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-1.02
Shares Outstanding15,637,361
10 Day Avg. Volume139,795
30 Day Avg. Volume82,366
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)7.01
Price to Sales (P/S)3.37
P/FCF Ratio-13.62
Enterprise Value/Market Cap286.63
Enterprise Value/Revenue5.71
Enterprise Value/Gross Profit9.44
Enterprise Value/Ebitda-26.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cardiff Lexington Business Overview & Revenue Model
Company Description
Headquartered in Fort Lauderdale, Florida, Cardiff Lexington Corporation, which was established in 2001, offers a diverse range of services. The company provides affordable housing solutions and comprehensive tax resolution services across the Uni...
Cardiff Lexington Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Sep 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.21M | 11.54M | 8.27M | 11.85M | 10.69M | 9.88M |
| Gross Profit | 6.17M | 7.21M | 4.43M | 8.29M | 6.63M | 6.11M |
| EBITDA | -2.21M | 5.65K | -107.90K | 5.23M | 3.41M | 2.67M |
| Net Income | -10.44M | -6.54M | -3.30M | 3.03M | -5.43M | 666.29K |
Balance Sheet | ||||||
| Total Assets | 30.68M | 29.09M | 23.93M | 20.75M | 13.34M | 15.30M |
| Cash, Cash Equivalents and Short-Term Investments | 217.65K | 318.54K | 1.19M | 866.94K | 219.09K | 580.97K |
| Total Debt | 23.14M | 18.91M | 9.72M | 6.36M | 3.90M | 2.98M |
| Total Liabilities | 27.10M | 26.01M | 16.32M | 14.12M | 14.81M | 14.56M |
| Stockholders Equity | 3.58M | 5.54M | 7.60M | 6.62M | -1.47M | 732.36K |
Cash Flow | ||||||
| Free Cash Flow | -2.77M | -2.85M | -2.65M | -1.72M | -1.14M | -1.05M |
| Operating Cash Flow | -2.77M | -2.85M | -2.65M | -1.72M | -1.14M | -1.05M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 3.27M | -2.32M |
| Financing Cash Flow | 2.43M | 1.98M | 2.98M | 2.37M | 788.79K | 3.68M |
Cardiff Lexington Technical Analysis
Negative
0.20
Price Trends
0.20
Negative
0.63
Negative
1.79
Negative
Market Momentum
-0.07
Negative
32.86
Neutral
-1.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CDIX, the sentiment is Negative. The current price of 0.2 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.20, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 32.86 is Neutral, neither overbought nor oversold. The STOCH value of -1.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CDIX.
Cardiff Lexington Risk Analysis
Cardiff Lexington disclosed 52 risk factors in its most recent earnings report. Cardiff Lexington reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cardiff Lexington Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $73.56M | -17.47 | -1.95% | 11.11% | 218.26% | 64.44% | |
58 Neutral | $48.10M | -1.70 | -15.20% | 18.94% | -82.20% | -978.39% | |
56 Neutral | $28.21M | -237.51 | -0.28% | 18.11% | -71.45% | 97.98% | |
54 Neutral | $68.75M | -1.54 | -32.53% | 23.64% | -11.06% | -288.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $45.42M | -0.88 | -41.00% | 55.84% | -11.85% | -800.20% | |
45 Neutral | $203.29K | -0.01 | -210.83% | ― | 0.31% | 6.99% |
* Healthcare Sector Average
CDIX
Cardiff Lexington
0.01
-3.02
-99.57%
BCIC
BCP Investment Corporation
5.94
-4.03
-40.44%
RAND
Rand Capital
9.50
-2.59
-21.40%
OFS
OFS Capital
3.59
-1.41
-28.14%
GECC
Great Elm Capital
4.95
-1.56
-23.93%
OCCI
OFS Credit Company
1.54
-2.22
-59.06%
Cardiff Lexington Corporate Events
Business Operations and StrategyM&A Transactions
Cardiff Lexington Plans Major Musculoskeletal Healthcare Acquisition
Positive
Sep 24, 2026
On September 24, 2026, Cardiff Lexington announced it had signed a letter of intent to acquire a multi-location musculoskeletal healthcare platform serving patients in several states, in a deal valued at up to $104 million. The proposed combinatio...
Business Operations and StrategyRegulatory Filings and Compliance
Cardiff Lexington Creates New A-1 Preferred Control Shares
Neutral
Sep 4, 2026
On August 31, 2026, Cardiff Lexington Corporation filed a certificate of designation in Nevada creating a new series A-1 preferred stock, limited to two shares and structured to rank senior to common stock, on parity with series A preferred, and j...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.